PRVB Provention Bio Inc.

6.04
+0.18  (+3%)
Previous Close 5.86
Open 5.92
Price To Book 6.36
Market Cap 237,597,183
Shares 39,337,282
Volume 260,154
Short Ratio
Av. Daily Volume 461,163
Stock charts supplied by TradingView

NewsSee all news

  1. Sean Doherty Joins Provention Bio Board of Directors

    OLDWICK, N.J., Sept. 26, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the

  2. Provention Bio to Present at the 2019 Cantor Global Healthcare Conference

    OLDWICK, N.J., Sept. 25, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that

  3. Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

    OLDWICK, N.J., Sept. 24, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its

  4. Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock

    OLDWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing

  5. Provention Bio Announces Proposed Public Offering of Common Stock

    OLDWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b top-line data May 8, 2019 noted primary safety and tolerability endpoint met but efficacy and other secondary endpoints were not met.
PRV-300
Ulcerative Colitis
Phase 3 trial initiation announced April 9, 2019. Enrollment to be completed in 2020.
PRV-031 (teplizumab)
Type 1 diabetes
Phase 2a data due 4Q 2019.
PRV-6527
Crohn's disease
Phase 2b trial to commence 2020.
PRV-015
Celiac disease
Phase 1b to commence in the coming weeks - noted August 6, 2019.
PRV-3279
Systemic Lupus Erythematosus (SLE) and Lupus nephritis (LN)

Latest News

  1. Sean Doherty Joins Provention Bio Board of Directors

    OLDWICK, N.J., Sept. 26, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the

  2. Provention Bio to Present at the 2019 Cantor Global Healthcare Conference

    OLDWICK, N.J., Sept. 25, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that

  3. Provention Bio Reiterates Regulatory Strategy for PRV-031 and Announces Completion of Follow-on Financing

    OLDWICK, N.J., Sept. 24, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reiterated its

  4. Provention Bio Announces Pricing of $40 Million Public Offering of Common Stock

    OLDWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing

  5. Provention Bio Announces Proposed Public Offering of Common Stock

    OLDWICK, N.J., Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it has

  6. Provention Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    OLDWICK, N.J., Sept. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that